title: What is the role of novel thrombopoietic agents in the management of acute leukemia?
abstract: The role of novel thrombopoietic agents in the management of acute leukemia is a tale of two molecules, romiplostim and eltrombopag. Both are thrombopoietin (TPO) receptor agonists with somewhat different mechanisms of action. Romiplostim is a peptide TPO receptor agonist that activates the TPO receptor by binding to it just like TPO. Eltrombopag is a nonpeptide TPO receptor agonist that activates the TPO receptor by binding to the transmembrane domain. Both TPO receptor agonists increase platelet counts in healthy humans and in those with immune thrombocytopenia. This review focuses on the potential these agents may have in supportive care of patients with acute leukemia.
authors.affiliation: Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02114, USA. Electronic address: dkuter@mgh.harvard.edu.
authors.forename: David J
authors.initials: DJ
authors.lastname: Kuter
mesh_terms: D000208:Acute Disease; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D011961:Receptors, Fc / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy; D013926:Thrombopoietin / Q000627:therapeutic use*
chemical_list: D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C082218:MPL protein, human; D013926:Thrombopoietin; C488777:romiplostim
keywords: Eltrombopag; Leukemia; MDS; Romiplostim; Supportive care; TPO; Thrombopoietin; rHuMGDF